Otsuka Precision Health

Otsuka Precision Health is a technology-focused subsidiary of Otsuka America, Inc. dedicated to providing personalized healthcare solutions through digital therapeutics and health technology. The company's primary focus is on mental health, specifically addressing unmet needs in major depressive disorder through innovative software-based interventions. Their flagship product, Rejoyn, is the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms. By combining data science, behavioral health, and digital tools, Otsuka Precision Health aims to bridge the gap between traditional pharmacology and patient-centered digital care. The organization operates as a specialized unit to accelerate the commercialization and adoption of digital medicine within the broader Otsuka portfolio.